Nanotechnology - Driven Innovations in Anticoagulant Delivery andAntidote Development for Hemostasis Regulation

Cardiovascular and Hematological Disorders - Drug Targets · Published 2026-07-23 · DOI 10.2174/011871529x423173251208100541

Authors (4)

Jitendra Maity, Sushil Kumar Singh, Sovan Lal Pal, Amlan Bishal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Maity, J., Singh, S., Pal, S., et al. (2026). Nanotechnology - Driven Innovations in Anticoagulant Delivery andAntidote Development for Hemostasis Regulation. Cardiovascular and Hematological Disorders - Drug Targets. https://doi.org/10.2174/011871529x423173251208100541

Related articles

• Targeting Neuropeptide Y: Novel Approaches to the Treatment of Cardiovascular and Haematological Disorders · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• IgG Kappa Multiple Myeloma with Cutaneous Plasmacytoma and Hypereosinophilic Leukocytosis in a Young Patient: A Rare Case Report · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Medication Adherence and Persistence to PCSK-9 Inhibitors from Marketing Authorization to the End of Direct Hospital Distribution at ASST Bergamo Ovest in Northern Italy: A Retrospective Observational Study · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Catestatin as a Marker of Cardiovascular Diseases · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Utilization Trends and Outcomes of Alteplase in Acute Cerebral Ischemia among Patients with Hypertension or Diabetes: A Tertiary Care Experience from Southern Punjab · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a) · Cardiovascular and Hematological Disorders - Drug Targets · 2026 · Same journal
• Therapeutic Trends in Diabetes Management: A Review on Oral Hypoglycemic Agents (OHAs) Utilization in Tertiary Care · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal
• Lipoprotein(a) Lowering with Pelacarsen (TQJ230) · Cardiovascular and Hematological Disorders - Drug Targets · 2025 · Same journal